|
市場調查報告書
|
本報告已在2012年04月11日停止出版。
更改為出版
Gene Therapy
出版日期 : 2012年02月
商品編碼: 236740
本報告書內容包括:全球的基因療法市場的調查、基因療法的概要和課題、對各種病症適用基因療法、全球各國的規範環境的分析、市場預測、市場加入企業100家的介紹等、內容綱要摘記如下:
第1章 介紹、調查方法、及產品定義
第2章 全球展望
- 基因療法：是否為未來有希望的治療法
- 已認定的基因療法勢力減少
第3章 市場趨勢
- 2009年：對基因療法業界來說是激動的一年
- 基因療法的希望
- 中國：全球首例的基因療法認可
- 主要市場仍期待基因療法的持續
- 癌症為基因療法的主要標的
- 腺病毒：基因療法所採用的主要載體
- 有效性：主要課題
- 亞洲的基因療法生產線的優勢 其他
第4章 全球的趨勢
- 合作和收購：成功策略
- 專利網
- 商品化
- 標的疾病和加入企業
- 生產線的藥劑概要
第5章 主要市場展望
第6章 基因療法：概要
- 分子的基礎知識
- 基因體：資訊網
- 何謂基因療法
- 基因療法的種類
- 各種對策
第7章 基因療法的構成因素
第8章 各種對策展望
第9章 疾病治療的基因療法
第10章 法律規範環境
第11章 研究開發
第12章 近年的業界活動
第13章 近年的企業活動
第14章 全球的主要企業
第15章 全球市場展望
企業介紹：100家
Abstract
This report analyzes the Global market for Gene Therapy in US$ Million. Annual
estimates and forecasts are provided for the period 2007 through 2015. The
report profiles 100 companies including many key and niche players such as
AnGes MG Inc., BioSante Pharmaceuticals, GenVec, Genzyme Corporation, Oxford
BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Transgene, and Vical Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select
online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
- Study Reliability and Reporting Limitations 1
- Disclaimers 2
- Data Interpretation & Reporting Level 2
- Quantitative Techniques & Analytics 3
- Product Definitions and Scope of Study 3
2. MARKET OUTLOOK 4
- Gene Therapy - Promising Therapy for Future? 4
- Approved Gene Therapies Fail to Gather Momentum 4
- Manufacturers Eye International Markets 5
3. MARKET DYNAMICS/TRENDS 6
- 2009 - A Tumultuous Year for Gene Therapy Industry 6
- Hope Floats in Gene Therapy 6
- China - First to Approve Gene Therapy Worldwide 7
- The Wait Continues for First Gene Therapy in Major Markets 7
- Table 1: Gene Therapy Clinical Development (2009): Percentage Share
Breakdown by Stage (includescorresponding Graph/Chart) 7
- Cancer Remains the Key Target for Gene Therapy 8
- Table 2: Clinical Development of Gene Therapy by Targeted Indication
(2009): Percentage Breakdown of Number ofTrials for Cancer Diseases,
Cardiovascular Diseases,Infectious Diseases, Monogenic Diseases,
Neurological Diseases and Others (includes correspondingGraph/Chart) 8
- Adenovirus - The Leading Vector Employed in Gene Therapy 8
- Table 3: Gene Therapy Clinical Development by VectorsUsed (2009):
Percentage Breakdown of Number of Trialsfor Adenovirus, Retrovirus, Plasmid
DNA, VacciniaVirus, Lipofection and Others (includescorresponding
Graph/Chart) 8
- Efficacy - The Key Challenge for Gene Therapy 8
- Gene Therapy Pipeline Strengthens in Asia 9
- Counting on the Success Factors 9
- Factors Influencing Gene Therapy Future Development 10
- Human Genome Analysis 10
- Gene Therapy - The Next Generation Cardiovascular Therapy 10
- Public Support for Gene Therapy 10
- RNAi Bodes Bright Prospects 10
- Factors Hampering Market Growth 10
- Stringent Regulatory Laws in US and Europe Prolong Gene Therapy
Development 10
- Identifying Genetic Fault 11
- Immune Response 11
- Delivering Genetic Materials into Patient Cells 11
- Multigene Disorders 12
- Side Effects 12
- Push Towards Germline Gene Transfer 12
- Technical Limitations 12
4. THE GLOBAL LANDSCAPE 13
- Alliances and Acquisitions - Strategy for Success 13
- Patent Pooling: Yet Another Obstacle 13
- Commercialization: A Road Uphill 13
- Time Line in Gene Therapy Drug Development 14
- Target Diseases and Players Involved 14
- Key Players by Application Area 15
- Table 4: Gene Therapy Clinical Trials Worldwide (2009): Percentage
Breakdown by Gene Type Transferred for Antigen, Cytokine, Tumor Suppressor,
Growth Factor, Deficiency, Suicide, and Others (includescorresponding
Graph/Chart) 15
- Table 5: Gene Therapy Clinical Trials (2007): Percentage Breakdown by
Geographic Region for US, Europe,Canada, Japan and Rest of World
(includescorresponding Graph/Chart) 16
- Select Gene Therapy Products in Phase III Development (2010) 16
- Select Gene Therapy Products in Phase II Development (2010) 16
- Select Gene Therapy Products in Phase I and Pre-Clinical Development
(2010) 17
- Overview of Select Drugs in Pipeline 17
- Allovectin-7(r) (Vical Inc.) 17
- Generx (Cardium Therapeutics) 18
- Trinam(r) (Ark Therapeutics) 18
- TroVax(r) (Oxford BioMedica) 18
- Collategene(tm) (AnGes MG Inc.) 19
5. REVIEW OF MAJOR MARKETS 20
- United States 20
- Regulatory Environment 20
- Food and Drug Administration 20
- FDA Requires Additional Toxicology and Biodistribution Studies 20
- IRB and IBC 21
- NIH 21
- Europe 22
- Germany and UK- The Hub of European Gene Therapy Market 22
- Table 6: Gene Therapy Clinical Trials in Europe (2007): Percentage
Breakdown of Number of Trials by Countryfor UK, Germany, Switzerland,
France, Belgium,Netherlands and Others (includes corresponding Graph/Chart)
23
- Regulatory Environment 23
- Gene Therapy Advisory Committee 23
- European Society of Gene and Cell Therapy (ESGCT) 24
- Study of Regulatory Environment in Select European Countries 24
- United Kingdom 24
- Germany 25
- Italy 25
- Sweden 25
- The Netherlands 25
- Switzerland 25
- Gene Therapy Industry in Europe and the US - A Comparison 25
- Japan 26
- Asia-Pacific 26
- Gene Therapy Industry in Europe and the US - A Comparison 26
- World' s First Gene Therapy Medicine Approved in China 27
- Prospects for Gendicine 27
- Competition 28
- Rest of World 28
6. GENE THERAPY - AN INSIGHT 29
- Molecular Basics - The Gene 29
- Genome - The Information Pool 29
- Functional Cloning 29
- Random Sequencing 29
- Positional Cloning 30
- What is Gene Therapy? 30
- A Backdrop 30
- 1990 Highlights - The Preliminary Gene Therapy Trial 30
- 1995 Highlights 30
- 2000 Highlights - Clinical Trials Reaches 400-Milestone 31
- 2004 Witnesses the First Gene Therapy Drug 31
- Classical Theory of Gene Therapy 31
- Ex-Vivo Approach of Gene Therapy 31
- In-vivo Approach of Gene Therapy 31
- Types of Gene Therapy 32
- Monogenic Gene Therapy 32
- Suicide Gene Therapy 32
- Antisense Gene Therapy 32
- Various Approaches 32
7. COMPONENTS OF GENE THERAPY 33
- Vector 33
- Delivery Vehicles and Challenges in Use of Viral Vectors 33
- Gene Delivery - Without Virus 33
- Non-Viral Products in Pipeline 34
- Well-known Delivery Approaches for Gene Therapy 34
- Viral and Non-viral Vectors in Use 35
- Retroviruses 35
- Adenoviruses 35
- Adenoassociated viruses 35
- Herpes simplex viruses 35
- Lentiviruses 35
- Liposomes 36
- Viral Vectors by Companies involved 36
- Gene Cassette 36
- Target cells 36
- Stem cells 36
- Differentiated cells 36
- The Disc: An Excellent Target for Gene Therapy 37
8. REVIEW OF VARIOUS APPROACHES 38
- Antisense Technology 38
- Catalytic Ribozyme Technology 38
- Triple Helix DNA 38
9. GENE THERAPY FOR DISEASE TREATMENT 40
- Gene Therapy for Cancer Treatment 40
- Gene Transfer and Gene Therapeutic Concepts in Cancer 40
- Competitive Landscape in Cancer Gene Therapy 41
- Gene Therapy Mechanism in Cancer 41
- Advantages Over Chemotherapy 42
- Developments in Cancer Gene Therapy 42
- P53 Gene Therapy - A Novel Approach in Cancer Treatment 42
- Gendicine - From Concept to Reality 43
- Vaccines 43
- Gene Therapy for Cardiovascular Disease 43
- Cardiovascular Gene Therapy Products under Trial 44
- Gene Therapy for Cystic Fibrosis Disease 44
- Gene Therapy for Haemophilia B 45
- Gene Therapy for AIDS/HIV 45
- Gene Therapy for Parkinson' s Disease 45
- The Disease 45
- Therapy 46
- Development Pipeline of Gene Therapies in Parkinson' s Disease 47
10. REGULATORY ENVIRONMENT 48
- Gene therapy and Regulatory Environment 48
- Gene Patents - An Overview 48
11. RESEARCH AND DEVELOPMENT 49
- Amsterdam Molecular Therapeutics to Develop Gene Therapy for Parkinson' s
Disease 49
- Researchers Develop Synthetic Gene Vectors to Reduce Body Immune Responses
49
- Illumina Brings Digital Gene Expression Applications 50
- MolMed Develops Gene Therapy Based Treatment for Skin Cancer 50
- Santaris Pharma Develops New Therapy to Lower Cholesterol Level 50
- Researchers Develop Gene Therapy for Severe Burns 50
- AMT Develops (AAV) Vector-Based Gene Therapy 51
- Ark Comes Up with New Gene Therapy Delivery Technology 51
12. RECENT INDUSTRY ACTIVITY 52
- Ceregene Initiates Enrolment for Phase IIb Study for CERE-120 in
Parkinson' s Disease 52
- Oxford BioMedica Releases Phase III Trial Results of TroVax(r) in Renal
Cancer 52
- AnGes To Carry Out Additional Trial for Collategene(tm) 52
- Vical Receives Positive Review for Allovectin-7(r) Phase III Trial 53
- Cardium and bioRASI Ink Master Services Agreement for Generx 53
- Ceregene Commences New Phase I/II Trial for CERE-120 in Parkinson' s
Disease 53
- GeneVec Discontinues TNFerade Trial in Pancreatic Cancer 53
- Transgene Grants Novartis an Option to Acquired License to TG4010 54
- Helmholtz and SIRION Team Up to Develop Gene Therapy for Lymphoid Tumors 54
- Targeted Genetics to Merge with Biocontrol 55
- BioSante Merges with Cell Genesys 55
- Targeted Genetics Sells Off Gene Therapy IP to Genzyme 55
- Ark Therapeutics Obtains Clearance for Cerepro for Named Patient Use 55
- StemCells Acquires Stem Cell Sciences 56
- FDA Clears Ark Therapeutics to Commence Phase III Clinical Trial of
Trinam(r) 56
- Introgen Therapeutics Files for Bankruptcy 56
- Cell Genesys Terminates ITAL-2 Trial of GVAX Vaccine in Advanced Prostate
Cancer 57
- Roche Takes Over Mirus Bio Corp. 57
- FDA Declines Accepting Approval Application for Advexin 57
- Transgene' s TG4010 Therapeutic Vaccine Meets Primary Endpoint in NSCLC 58
- Ark Therapeutics Obtains SPA for Phase III Study of Trinam(r) from FDA 58
- International Consolidated Acquires China Gene 58
- Ark Therapeutics Acquires Lymphatix 58
- Oxford BioMedica Obtains Rights for RNAi Technology 59
- Gene Bridges Inks Licensing Agreement with Genencor 59
- AMT Enters into R&D Agreement with NIH 59
- VGX Inks Supply Agreement with a U.K. Consortium 60
13. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 61
- Cardium Therapeutics Receives Fast Track Designation for Generx(tm) 61
- Oxford Biomedica' s ProSavin Enters Phase I/II Trial 61
- Lentigen Acquires Gene Delivery Technology from Cell Genesys 61
- VIRxSYS Acquires SMaRT(tm) RNA Technology 61
- Gene Logic Divests Genomics Assets 62
- Genzyme Inks Agreement with Ceregene 62
- Silence Therapeutics Extends Agreement with Quark 62
- Benda Inks HIV Vaccine Joint Venture with DNAVEC 62
- Research Dynamics Bags Contract for Multicenter Clinical Study 62
- Thermo Fischer Collaborates with Lentigen to Develop Gene-Silencing
Technology 63
- Fovea Enters into Collaboration with GENZYME Corporation 63
- Oxford BioMedica Inks Licensing Agreement with Children' s Hospital 63
- Sigma and Oxford Sign Joint License Agreement for LentiVector Technology 63
- Benda Attains Additional Stake in SiBiono 64
- Oxford BioMedica Acquires Oxxon 64
- Oxford BioMedica and Sanofi-Aventis Agrees to Co-Develop and Market TroVax
64
- Illumina Completes Acquisition of Solexa 64
- RheoGene Plans Merger with Intrexon 65
- Covalon Acquires Gene Therapy Technology from Perfusion 65
- Inovio Takes Over DNA Expression and Delivery Assets of Valentis 65
- Mologen Inks Agreement with ONCO 65
- Aida Acquires Controlling Stake in Qiaer 66
- Neurologix Inks Licensing Agreement with Diamyd Medical' s Subsidiary 66
- Takara Inks Collaboration Agreement with Chinese Center for Disease
Control 66
- JDRF Collaborates with Genzyme Corp and AGTC 66
- Galapagos Collaborates with Arthrogen 67
- Genzyme Acquires Avigen' s Gene Therapy Assets 67
- Diamyd Acquires Nurel 67
- Oxford BioMedica Accords with Sigma-Alrdrich 67
- Oxford BioMedica Inks Licensing Agreement with Pfizer 68
- genOway Acquires IngenKO Pty Ltd 68
- Crucell Strikes a Deal with Two Asian Firms 68
- Corautus' VEGF-2 Gene Therapy Gains Recognition from US FDA 68
- ViroMed Ceases Development of Gene Therapy 68
- Corautus Genetics Pacts with CSEMC 68
- Takara Bio Collaborates with Mie University 69
- Celladon Accords with V-Kardia 69
- Genzyme Acquires Ilex Oncology 69
- Genzyme and AGTC Form Collaboration 69
- Sanofi-Synthelabo Merges with Aventis 69
- Guidant Forms Collaboration with Columbia and Stony Brook 70
- Louisiana and Bionomics Team-Up 70
- Avigen Receives FDA Clearance to Commence Phase I/II Clinical Trial of
Av201 70
- Oxford BioMedica and Viragen Enters into Licensing Agreement 70
- Oxford BioMedica Signs Licensing Agreement with Merck 70
- Avigen Starts Gene Therapy Trial for Parkinson' s Disease 70
- Oxford BioMedica Acquires Chiron Patents 71
- UA duo Establishes Gene-therapy Firm 71
- SiBiono Commences Construction of Gene Therapy Facility 71
- Avigen Receives FDA Approval for Clinical Trial of AV201 71
- UK GTAC Approves Clinical Trial 71
- CYGEE Bags patent Approval for Novel Gene Therapy Technology 72
- Mirus Bio Receives $1.26 million SBIR Grant 72
- CEGE Trials Novel Gene Therapy 72
- Avigen Suspends Haemophilia Gene Therapy Trials 72
- Oxford BioMedica and RPR Enters into Licensing Agreement 72
- Schering AG Acquires Collateral Therapeutics 72
- MolMed SpA Buys Rights to RectroNectin 73
- Avigen Receives US FDA Approval 73
- Targeted Genetics Receives Patents 73
- Enzo Biochem Conducts Phase I Studies Related to HIV Treatment 73
- Eurogene Acquires Oy Quattrogene 73
- Cardion AG Acquires Tolerance Pharmaceuticals 74
- Aventis Restructures Gene-Therapy Alliance with Introgen 74
- Boehringer Ingelheim Austria GmbH Inks Agreement with BIA Separations 74
- Cell Genesys Establishes New Subsidiary 74
- Chiron Divests Gene Therapy Manufacturing Facility 74
- ViroMed Conducts Clinical Trials on Gene Therapy Drug 74
- EG009 Gene Therapy Doubles Survival Rate of Malignant Glioma Patients in
Phase I/II Clinical Trials 75
- Genteric Receives Patent for Insulin Gene Pill System 75
- Bayer Corp. Receives Marketing and Distribution Rights to Coagulin-B 75
- Avigen Receives Patent for Parkinson' s Disease Gene Therapy 75
- Aventis Acquires License form Electrofect 75
- DeveloGen Acquires Hepavec 75
- Targeted Genetics Acquires Genovo Inc 76
- GenStar Acquires Allegro Inc 76
- Argonex and Rohm & Haas Company Enter into a Joint Venture 76
- Nexell Therapeutics and Takara Shuzo Join Forces 76
- BTG International Inks Licensing Agreement with Avigen 76
- Oxford BioMedica Awarded US Patents Concerning Retroviral and Lentiviral
Systems 77
- Genteric Receives Gene Therapy Patent 77
- GenVec Granted Broad Gene Therapy Patent 77
14. FOCUS ON SELECT GLOBAL PLAYERS 78
- AnGes MG, Inc. (Japan) 78
- BioSante Pharmaceuticals (US) 78
- GenVec (US) 79
- Genzyme Corp. (US) 80
- Oxford BioMedica (UK) 80
- Shenzhen SiBiono GeneTech Co., Ltd (China) 81
- Transgene (France) 81
- Vical, Inc. (US) 81
15. GLOBAL MARKET PERSPECTIVE 82
- Table 7: World Current & Future Market Analysis forGene Therapy -
Annual Sales Figures in US$ Millionfor Years 2007 through 2015
(includescorresponding Graph/Chart) 82
COMPETITIVE LANDSCAPE
|
